New lens aims to restore vision at all distances after cataract surgery

NCT ID NCT07696130

Recruiting now Disease control Sponsor: Pomeranian Medical University Szczecin Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests a new type of lens, called the enVista Envy, implanted during cataract surgery. The lens is designed to help people see clearly at far, intermediate, and near distances, while reducing common side effects like glare and halos. Twenty adults with cataracts or presbyopia will receive the lens in both eyes and be followed for six months to measure vision quality, complications, and how quickly the brain adapts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enVista Envy trifocal intraocular lens
What this could lead to: If successful, this lens could help people see clearly at far, intermediate, and near distances after cataract surgery, reducing the need for glasses.
What could go wrong: This is a small, early study with only 20 participants, so results may not apply to everyone. Some people may still experience glare or halos.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT CATARACT (POST-OPERATIVE CATARACT SURGERY FOLLOW-UP)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

II Department of Ophthalmology, Pomeranian Medical University
RECRUITING

Szczecin, Zachodnipomorskie, 70-111, Poland

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.